ArticlebioRxiv : the preprint server for biology2026
Validation of an oral self-administration model of xylazine use in mice.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Xylazine is a pervasive adulterant in clandestine opioid supplies. This trend is troubling, as xylazine carries its own acute side effects and its long-term cognitive and motivational effects are not known. Thus, we developed and validated a model of oral xylazine self-administration that is conducive to polysubstance studies and can easily be implemented in animal research labs. Mice underwent 4-hour drinking sessions where their only source of drinking water was adulterated with xylazine (10-1000μg/mL). Oral bioavailability and brain penetrance were validated using mass spectrometry on brain and plasma samples collected after a drinking session. Male and female mice decreased fluid intake at high concentrations of xylazine, with male mice consuming less than female mice at intermediate concentrations (100 and 300μg/mL). Female mice had decreased locomotion following drinking sessions at 100, 300, and 1000μg/mL. After a 4-hour drinking session, all mice received brain xylazine concentrations that are above the Ki (affinity) and EC50 (potency) of several known binding targets of xylazine. We then performed a three-bottle choice experiment where mice had the option of drinking from water with xylazine, water with fentanyl, or plain water. In three-bottle choice, mice consumed less xylazine-containing water than fentanyl-containing or plain water. Our results indicate that xylazine is orally bioavailable in mice, that mice will readily drink xylazine to pharmacologically and behaviorally relevant doses, and that mice prefer consuming fentanyl and water over xylazine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.